Hemophilia B (Factor IX Deficiency) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Hemophilia B (Factor IX Deficiency) – Pipeline Review, H2 2019’, provides an overview of the Hemophilia B (Factor IX Deficiency) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hemophilia B (Factor IX Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemophilia B (Factor IX Deficiency) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Hemophilia B (Factor IX Deficiency)

– The report reviews pipeline therapeutics for Hemophilia B (Factor IX Deficiency) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hemophilia B (Factor IX Deficiency) therapeutics and enlists all their major and minor projects

– The report assesses Hemophilia B (Factor IX Deficiency) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hemophilia B (Factor IX Deficiency)”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hemophilia B

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hemophilia B pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“ApcinteX Ltd

ASC Therapeutics Inc

Catalyst Biosciences Inc

Chengdu Rongsheng Pharmaceutical Co Ltd

China Biologic Products Holdings Inc

Daiichi Sankyo Co Ltd

Expression Therapeutics LLC

Freeline Therapeutics Ltd

GC Pharma

Genzyme Corp

Intellia Therapeutics Inc

LFB SA

Logicbio Therapeutics Inc

Novo Nordisk AS

OPKO Biologics Ltd

Pfizer Inc

RegenxBio Inc

Sangamo Therapeutics Inc

Sanofi

Shenzhen Weiwu Guangming Biological Preparations Co Ltd

Sigilon Therapeutics Inc

Takeda Pharmaceutical Co Ltd

UniQure NV”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Hemophilia B Overview 6

Hemophilia B Therapeutics Development 7

Hemophilia B Therapeutics Assessment 16

Hemophilia B Companies Involved in Therapeutics Development 24

Hemophilia B Drug Profiles 35

Hemophilia B Dormant Projects 117

Hemophilia B Discontinued Products 118

Hemophilia B Product Development Milestones 119

Appendix 130

List of Tables

“List of Tables

Number of Products under Development for Hemophilia B (Factor IX Deficiency), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by ApcinteX Ltd, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by ASC Therapeutics Inc, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Catalyst Biosciences Inc, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by China Biologic Products Holdings Inc, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Daiichi Sankyo Co Ltd, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Expression Therapeutics LLC, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Freeline Therapeutics Ltd, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by GC Pharma, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Genzyme Corp, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Intellia Therapeutics Inc, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by LFB SA, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Logicbio Therapeutics Inc, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Novo Nordisk AS, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by OPKO Biologics Ltd, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Pfizer Inc, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by RegenxBio Inc, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Sangamo Therapeutics Inc, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Sanofi, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Shenzhen Weiwu Guangming Biological Preparations Co Ltd, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Sigilon Therapeutics Inc, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Hemophilia B (Factor IX Deficiency) – Pipeline by UniQure NV, H2 2019

Hemophilia B (Factor IX Deficiency) – Dormant Projects, H2 2019

Hemophilia B (Factor IX Deficiency) – Dormant Projects, H2 2019 (Contd..1), H2 2019

Hemophilia B (Factor IX Deficiency) – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Hemophilia B (Factor IX Deficiency), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports